Partnering opportunity

French Technology Transfer Office offers new solid cancer treatment targeting cancer stem-cells


A French Technology Transfer Office (TTO) offers an innovative treatment targeting solid tumors. The innovation is based on a specified and patented hit molecule which strongly reduces the activity of CSCs (Cancer Stem-like Cells). The french TTO is looking for interested pharmacology corporates or biotechnology SMEs, either for a licensing agreement or a technical cooperation agreement. Research cooperation agreement is also open with R&D institutions working in oncology research.

Partner sought

The Technology Transfer Office is looking for Licensing or a technical cooperation agreement with : - national or multinational corporates of drugs market and pharmacology business, - Small and Medium-sized companies, startups, acting on biotechnology markety Research cooperation agreement is also open to discussion with any R&D institution working in the field of oncology research.


A French TTO acting on behalf major life science research labs in Paris Region, has developed a new patented hit molecule which strongly reduces the activity of the CSCs within solid tumors. CSCs are specific cells with self-renewal capacities whose no signaling pathway has been identified and used up to now. State-of-the-art of solid cancer treatments : CSCs activity is known to be a significant factor in solid cancer initiation and growth. Among all therapies, none has been proved to be efficient in reducing CSCs activity. A life-science research lab has identified a signaling pathway which is specific to the self-renewal properties of the CSCs. Current stage of the technology : A new hit molecule which inhibites a cell surface receptor of the above-mentioned specific signaling pathway in the CSCs, has been identified in glioblastoma. The proof of concept of such inhibition using this new hit molecule has been done ex vivo and in vivo using several xenografted mice. A PCT patent has been applied in 2015. Other mice models are investigated. Batching and safety studies are in progress. Requested partnership : A licensing agreement is open to manufacturing drug corporates which are able to drive clinical testing of the new hit molecule, prior to its manufacturing and commercialization. A technical cooperation agreement may also interest companies in biotechnology which are interested to work with the French research team in order to extend the pre-clinical trials to other animal models. A research cooperation is open to R&D institutions operating in oncology research, in order to improve the knowledge in targeting cancer stem-like cells with a view to find new means for solid cancer treatment.

Advantages and innovations

The newly found hit molecule has got competitive advantages since it offers the first efficient treatment for glioblastoma which targets cancer stem-like cells, strongly implicated in tumor initiation and therapeutic resistance. First, the new hit molecule have an efficient impact in reducing solid brain cancer growth (initiation or relapse). Secondly, the new hit molecule cuts through solid brain cancer radiotherapy and up-to-now chemotherapy resistance. Finally, because the signaling pathway is specific to the self-renewal properties of the CSCs, it gives opportunities for potential treatment for other solid tumors.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company